<DOC>
	<DOCNO>NCT01673438</DOCNO>
	<brief_summary>This phase 1b open-label study investigate safety maximum tolerate dose aldoxorubicin plus doxorubicin HCl adminstered infusion every 3 week 8 cycle subject advance solid tumor .</brief_summary>
	<brief_title>Phase 1b Study Investigate Safety Maximum Tolerated Dose Aldoxorubicin ( INNO-206 ) Plus Doxorubicin HCL Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>An Open-Label Phase 1b Study Investigate Safety Maximum Tolerated Dose Aldoxorubicin ( INNO-206 ) Plus Doxorubicin HCl Administered Infusions Every 3 Weeks Subjects Advanced Solid Tumors</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Age ≥ 18 year , male female . 2 . Histologically cytologically confirm malignant solid tumor relapse refractory standard therapy standard chemotherapy exist . 3 . Capable provide informed consent comply trial procedure . 4 . Baseline absolute leave ventricular ejection fraction ( LVEF ) measure scintigraphically ( MUGA , myocardial scintigram ) ultrasound ( echocardiogram ) ≥ Institutional Lower Limit Normal . 5 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 . 6 . Life expectancy &gt; 12 week . 7 . Measurable evaluable disease accord RECIST 1.1 criteria.15 8 . Women must able become pregnant ( e.g. , postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . [ Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ] 9 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 10 . Geographic accessibility site ensures subject able keep studyrelated appointment . 1 . Palliative surgery , chemotherapy , immunotherapy and/or radiation treatment &lt; 4 week prior Screening Visit . 2 . Prior treatment ≥ 150 mg/m2 doxorubicin HCl Doxil® cumulative dose , epirubicin ≥ 150 mg/m2 . 3 . Exposure investigational agent within 30 day Randomization . 4 . Evidence active uncontrolled central nervous system ( CNS ) metastasis ( negative imaging study perform due suspicion CNS metastasis within 4 week Screening Visit ) . 5 . History malignancy except cure basal cell carcinoma , squamous cell carcinoma , superficial bladder cancer carcinoma situ cervix . 6 . Laboratory value : Screening serum creatinine ≥ 2 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time ULN liver metastases 5 time ULN liver metastasis , total bilirubin &gt; 2 time ULN , white blood cell ( WBC ) count &lt; 3500/mm3 , absolute neutrophil count ( ANC ) &lt; 1500/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 25 % female &lt; 27 % male , coagulation test ( prothrombin time [ PT ] ; partial thromboplastin time [ PTT ] ) , International Normalized Ration ( INR ) &gt; 1.5 time ULN , serum albumin &lt; 2.0g/dL . 7 . Clinically evident congestive heart failure ( CHF ) &gt; class II New York Heart Association ( NYHA ) guideline . 8 . Baseline QTc &gt; 470 msec and/or previous history QT prolongation take medication . Concomitant use medication associate high incidence QTc prolongation allow . 9 . Serious clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. 10 . History sign active coronary artery disease without angina pectoris .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>aldoxorubicin</keyword>
	<keyword>phase 1</keyword>
	<keyword>INNO-206</keyword>
	<keyword>doxorubicin</keyword>
</DOC>